BeiGene
BGNE
$164.88
Share price
2.56%
Change (1 day)
-31.37%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
P/S ratio for BeiGene (BGNE)
P/S ratio as of May 2024 (TTM): 7.61
According to BeiGene 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.60629. At the end of 2023 the company had a P/S ratio of 8.06.
P/S ratio history for BeiGene from 2016 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 8.06 | -51.36% |
| 2022 | 16.6 | -29.1% |
| 2021 | 23.4 | -69.96% |
| 2020 | 77.8 | 223.81% |
| 2019 | 24.0 | -42.86% |
| 2018 | 42.0 | 125.23% |
| 2017 | 18.7 | -98.34% |
| 2016 | > 1000 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | 1.09 | -85.67% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | 92.5 | 1,116.08% | 🇺🇸 USA |